Moeno Kume

Moeno Kume

Auto-generated profile, based on publicly available information

Moeno Kume

Department of Neuroscience, The University of Texas at Dallas, Richardson, TX, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
AWAndi Wangzhou
Andi Wangzhou
CPCandler Paige
Candler Paige
SNSanjay V. Neerukonda
Sanjay V. Neerukonda
DNDhananjay K. Naik
Dhananjay K. Naik
MKMoeno Kume
Moeno Kume
TPTheodore J. Price
Theodore J. Price
Single-cell gene expression analysis predicts pain signaling pathways between sensory neurons and peripheral cell types.

5 December 2022 in British Journal of Pharmacology
Verified
Journal Article
Closed access
HSHillary V. Schiff
Hillary V. Schiff
CRCandy M. Rivas
Candy M. Rivas
WPWilliam Pederson
William Pederson
ESEstevan Sandoval
Estevan Sandoval
SGSamuel Gillman
Samuel Gillman
SBScott Boitano
Scott Boitano

3 November 2022 in The Journal of Pain
Verified
Journal Article
Open access
ISIshwarya Sankaranarayanan
Ishwarya Sankaranarayanan
DTDiana Tavares-Ferreira
Diana Tavares-Ferreira
LHLucy He
Lucy He
MKMoeno Kume
Moeno Kume
JMJuliet M. Mwirigi
Juliet M. Mwirigi
TPTheodore J. Price
Theodore J. Price
Chemotherapy-induced peripheral neuropathy is a challenging condition to treat, and arises due to severe, dose-limiting toxicity of chemotherapeutic drugs such as paclitaxel. This often results in debilitating sensory and motor deficits that are not effectively prevented or alleviated by existing therapeutic interventions. Recent studies have demonstrated the therapeutic effects of Meteorin, a neurotrophic factor, in reversing neuropathic pain in rodent models of peripheral nerve injury induced by physical trauma. Here, we sought to investigate the potential antinociceptive effects of recombinant mouse Meteorin (rmMeteorin) using a paclitaxel-induced peripheral neuropathy model in male and female mice. Paclitaxel treatment (4 × 4 mg/kg, i.p.) induced hind paw mechanical hypersensitivity by day 8 after treatment. Thereafter, in a reversal dosing paradigm, five repeated injections of rmMeteorin (.5 and 1.8 mg/kg s.c. respectively) administered over 9 days produced a significant and long-lasting attenuation of mechanical hypersensitivity in both sexes. Additionally, administration of rmMeteorin ( .5 and 1.8 mg/kg), initiated before and during paclitaxel treatment (prevention dosing paradigm), reduced the establishment of hind paw mechanical hypersensitivity. Repeated systemic administration of rmMeteorin in both dosing paradigms decreased histochemical signs of satellite glial cell reactivity as measured by glutamine synthetase and connexin 43 protein expression in the dorsal root ganglion. Additionally, in the prevention administration paradigm rmMeteorin had a protective effect against paclitaxel-induced loss of intraepidermal nerve fibers. Our findings indicate that rmMeteorin has a robust and sustained antinociceptive effect in the paclitaxel-induced peripheral neuropathy model and the development of recombinant human Meteorin could be a novel and effective therapeutic for chemotherapy-induced peripheral neuropathy treatment. PERSPECTIVE: Chemotherapy neuropathy is a major clinical problem that decreases quality of life for cancer patients and survivors. Our experiments demonstrate that Meteorin treatment alleviates pain-related behaviors, and signs of neurotoxicity in a mouse model of paclitaxel neuropathy.

12 June 2023 in The Journal of Pain
Verified
Journal Article
Closed access
MKMoeno Kume
Moeno Kume
AAAyesha Ahmad
Ayesha Ahmad
KDKathryn A. DeFea
Kathryn A. DeFea
JVJosef Vagner
Josef Vagner
GDGreg Dussor
Greg Dussor
TPTheodore J. Price
Theodore J. Price

9 January 2021 in The Journal of Pain
Verified
Journal Article
Closed access
JMJuliet Mwirigi
Juliet Mwirigi
MKMoeno Kume
Moeno Kume
SHShayne N. Hassler
Shayne N. Hassler
AAAyesha Ahmad
Ayesha Ahmad
PRPradipta R. Ray
Pradipta R. Ray
TPTheodore J. Price
Theodore J. Price

20 November 2022 in The Journal of Pain
Verified
Journal Article
Open access
MKMoeno Kume
Moeno Kume
AAAyesha Ahmad
Ayesha Ahmad
SSStephanie Shiers
Stephanie Shiers
Michael D. BurtonMichael D. Burton
Michael D. Burton
KDKathryn A. DeFea
Kathryn A. DeFea
TPTheodore J. Price
Theodore J. Price
Our work provides evidence that PAR2 antagonists that only block certain aspects of signaling by the receptor can be effective for blocking protease-evoked pain in mice. This is important because it creates a rationale for developing safer PAR2-targeting approaches for pain treatment.